GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

SP-0230 is under clinical development by Sanofi and currently in Phase II for Neisseria meningitidis Infections.

Sanofi's SNY short percent of float has fallen 15.0% since its last report. The company recently reported that it has 3.74 ...

Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal ...

SK bioscience and Sanofi have expanded their agreement to jointly develop pneumococcal conjugate vaccines (PCVs) targeting ...

In connection with the start of the phase 3 trials of PCV21, Sanofi has expanded its alliance with South Korea-based SK Bio, ...

We recently compiled a list of the 10 Best European Dividend Stocks To Buy. In this article, we are going to take a look at ...

French pharma major Sanofi says it has entered into a new chapter of the collaboration with South Korean firm SK bioscience ...

The increases are to list prices, which do not include rebates to pharmacy benefit managers and other discounts.

In the current session, Sanofi Inc. SNY -0.18% + Free Alerts is trading at $48.30, after a 0.18% decrease. Over the past ...

JERUSALEM, Dec 17 (Reuters) - (This Dec.17 story has been corrected to say the results were for ulcerative colitis, not for both the diseases, in paragraph 5) Teva and Sanofi said last year they ...

State Street Corp raised its holdings in Sanofi (NASDAQ:SNY – Free Report) by 0.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The ...